Alentis Therapeutics AG

Alentis Therapeutics, the Claudin-1 company, is a clinical-stage biotech developing breakthrough treatments for Claudin-1 positive tumors and organ fibrosis. Alentis is the only company pioneering a novel approach to modify and reverse the course of disease by targeting Claudin-1, a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease.

Alentis was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert, MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in pharma-biotech hub Basel, Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US.